Erlotinib in the treatment of non-small cell lung cancer: Current status and future developments

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1301-1310

  Gridelli, Cesare ^a   Maione, Paolo ^a   Bareschino, Maria Anna ^a   Schettino, Clorinda ^a   Sacco, Paola Claudia ^a   Ambrosio, Rita ^a   Barbato, Valentina ^a   Falanga, Marzia ^a   Rossi, Antonio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

EGFR; Erlotinib; Lung cancer; NSCLC; Review; Tyrosine kinase inhibitors

Indexed keywords

AMPHIREGULIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; K RAS PROTEIN; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR ALPHA;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CIGARETTE SMOKING; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; ETHNICITY; FATIGUE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE ACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HAZARD RATIO; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; METASTASIS; MOLECULAR GENETICS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; REVIEW; SMOKING; SURVIVAL TIME; THERAPY EFFECT; TISSUE CHARACTERIZATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77953750636     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlaiotis A, Spitznagel EL and Piccirillo J: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 24: 4539-4544, 2006.
2. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connel M, Shepherd FA and Johnson BE: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19: 1734-1742, 2001.
3. Perez-Soler R: HER1/EGFR targeting: refining the strategy. Oncologist 9: 58-67, 2004.
4. Mass RD: The HER receptor family: A rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58: 932-940, 2004.
5. Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, Hittelman WN, Yu R, Lee JJ and Hong WK: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2: 1787-1793, 1996.
6. Rossi A, Galetta D and Gridelli C: Biological prognostic and predictive factors in lung cancer. Oncology 77(Suppl 1): 90-96, 2009.
7. John T, Liu G and Tsao MS: Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28(Suppl 1): S14-S23, 2009.
8. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
9. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD and Gazdar AF: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005. (Pubitemid 40425952)
10. Kolesar J, Brahmer J, Lee J, Guaglianone P, Patel J, Keppen M, Hidalgo M, Carbone D and Schiller J: Final results of ECOG 3503: a pilot study to determine if downstream markers of EGFR linked signalling pathways predict response to erlotinib (OSI-774) in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S): 406s (abstr 7588), 2007.
11. Mountain C: Revisions in the international system for staging lung cancer. Chest 777: 1710-1717, 1997. (Pubitemid 27260107)
12. Pisters KMW, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Sommerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC and Shepherd FA: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline. J Clin Oncol 25: 5506-5518, 2007. (Pubitemid 350232227)
13. Richardson F, Richardson K, Sennello G, Young D, Orlov S, Pápai-Székely Z, Keshavjee S, Kim J, Cerfolio R and Shepherd FA: Biomarker analysis from completely resected NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). J Clin Oncol 27(15S): 387s (abstr 7520), 2009.
14. http://www.cancer.gov/ (accessed on November 22, 2009).
15. Janjing YY, Park BJ, Kris MG, Miller VA, Riely GJ, Zheng J, Dycoco JP, Shen R and Azzoli CG: Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. J Clin Oncol 27(15S): 387s (abstr 7523), 2009.
16. Guida C, Maione P, Rossi A, Bareschino M, Schettino C, Barzaghi D, Elmo M and Gridelli C: Combined chemoradiotherapy for locally advanced non-small cell lung cancer: current status and future development. Crit Rev Oncol Hematol 68: 222-232, 2008.
17. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R and Vokes EE: Phase I trial of erlotinib-based multimodality therapy for inoperable stage HI non-small cell lung cancer. J Thorac Oncol 3: 1003-1011, 2008.
18. Martinez E, Martinez M, Casas F, Vinolas N, Minguez J, Paredes A, Perez Casa AM, Domine M, de la Torre A and Valcarcel F: Feasibility and tolerability of the addition of erlotinib to 3D thoracic (RT) in patients (P) with unresectable NSCLC: A prospective randomized phase II study. Ann Oncol 19(Suppl 8): viii100 (abstr. 263P), 2008.
19. Socinski MA, Stinchcombe TE, Halle JS, Moore DT, Petty WJ, Blackstock AW, Gettinger SN, Decker RH, Khandani AH and Morris DE: Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 27(18S): 389s (abstr 7528), 2009.
20. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH and Miller VA: TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23: 5892-5899, 2005.
21. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S and Hillan KJ: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23: 5900-5909, 2005.
22. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, Milanowski J, Karnicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM and von Pawel J: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552, 2007.
23. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudovo AW, Jin K, Johnston M, Chui W and Lee JS: Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 27: 5080-5087, 2009.
24. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D and Soria JC: Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 72: 6049-6055, 2006.
25. Akerley W, Boucher KM, Bentz JS, Arbogast K and Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol 4: 214-219, 2009.
26. Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C and Perrone F: An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer 9: 235-238, 2008.
27. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanvi M, Pao W and Johnson DH: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26: 1472-1478, 2008.
28. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C and Lee JS: Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65: 351-354, 2009.
29. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE and Janne PA: Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol 27(15S): 423s (abstr 8065), 2009.
30. Mok TS, Zhou C, Kim S, Wu Y and Perng R: Efficacy and safety of erlotinib in >1200 East/South-East (E/SE) Asian patients (pts) with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 26(755): 706s (abstr 19001), 2008.
31. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Janne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV and Johnson BE: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 75: 5267-5273, 2009.
32. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majern M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzales-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ and Taron M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 367: 958-967, 2009.
33. Gridelli C, Maione P, Rossi A, Ferrara ML, Bareschino MA, Schettino C, Sacco PC and Ciardiello F: Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early-second line? Oncologist 14: 137-147, 2009.
34. Cappuzzo F, Coudert B, Wierzbicki R, Park K, Custers F, Curbera GA, Giaccone G, Hilbe W, Klingelschmitt G and Ciuleanu TE: Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). Eur J Cancer Supplements 7(3): 12 (abstr 22LBA), 2009.
35. Brugger W, Kim JH, Hansen O, Sullivan R, White S, Lee JS, Schlegel M, Noe J, Nagelmeier I and Cappuzzo F: Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC. Eur J Cancer Supplements 7(2): 559 (abstr P-9176), 2009.
36. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Bigley AL and Hennequin LF: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655, 2002.
37. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J and Tortora G: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747, 2000.
38. Miller VA, O'Connor P, Soh C and Kabbinavar F: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27(18S): 799s (abstr LBA8002), 2009.
39. Johnson B, Miller V, Amler L, Stern H, Soh C, O'Connor P and Kabbinavar F: Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advance. Eur J Cancer Supplements 7(3): 5 (abstr 8LBA), 2009.
40. Shepherd FA, Perira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, MaoleeKoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
41. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M and Shepherd FA: Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24: 3831-3837, 2006.
42. Clark GM, Zborowski DM, Sanatabarbara P, Ding K, Whitehead M, Seymour L and Shepherd FA: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7: 389-394, 2006.
43. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Karnel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J and Shepherd FA: Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 353: 133-144, 2005.
44. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA and Tsao MS: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
45. Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J and Price A: Overcoming CYP1A1/1A2-mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27: 1220-1226, 2009.
46. Hainsworth J and Herbst R: A phase III, multicenter, placebo-controlled, double-blind, randomizaed clinical trial to evaluate the efficacy of bevacizumab (AVASTIN®) incombination with erlotinib (TARCEVA®) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). J Thorac Oncol 3(Suppl 4): S302 (abstr 189).
47. Wu Y, Zhang L, Siu-Kie Au L, Cheng A, Park K, Kim H, Srimuninnimit V, Sriuranpong V, Lin M and Kuo H: Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): initial results from the East/South East (E/SE) Asian subgroup. J Clin Oncol 25(18S): 685s (abstr 18018), 2007.
48. Schneider CP, Heigener D, Schott-von-Romer K, Gutz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C and Reck M: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. J Thorac Oncol 3: 1446-1453, 2008.
49. Tiseo M, Gridelli C, Cascinu S, Crinò L, Piantedosi FV, Grossi F, Brandes AA, Labianca R, Siena S, Amoroso D, Belvedere O, Valentino B, Bearz A, Venturino P and Ardizzoni A: An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. Lung Cancer 64: 199-206, 2009.
50. Pao W, Miller WA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73, 2005.
51. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
52. Nguyen KS, Kobayashi S and Costa DB: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 70: 281-289, 2009.
53. Gridelli C, Rossi A, Mongillo F, Bareschino M, Maione P and Ciardiello F: A randomized phase II study of sorafenib/ gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 8: 396-398, 2007. (Pubitemid 46918286)